High‐level expression of ARID1A predicts a favourable outcome in triple‐negative breast cancer patients receiving paclitaxel‐based chemotherapy

• Published in: Journal of cellular and molecular medicine Vol. 22; no. 4; pp. 2458 - 2468
• Main Authors: Lin, Yuan‐Feng, Tseng, Ing‐Jy, Kuo, Chih‐Jung, Lin, Hui‐Yu, Chiu, I‐Jen, Chiu, Hui‐Wen
• Format: Journal Article
• Language: English
• Published: England John Wiley & Sons, Inc 01.04.2018; John Wiley and Sons Inc
• Subjects: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols - pharmacology; ARID1A; Breast cancer; Cell Line, Tumor; Chemotherapy; Disease-Free Survival; DNA-Binding Proteins; Drug Resistance, Neoplasm - genetics; Female; Gene Expression Regulation, Neoplastic - drug effects; Humans; Indoles - pharmacology; Kaplan-Meier Estimate; Middle Aged; Nuclear Proteins - genetics; Original; p38 Mitogen-Activated Protein Kinases - genetics; p38MAPK; Paclitaxel; Paclitaxel - administration & dosage; Paclitaxel - adverse effects; Patients; Transcription; Transcription Factors - genetics; Triple Negative Breast Neoplasms - drug therapy; Triple Negative Breast Neoplasms - genetics; Triple Negative Breast Neoplasms - pathology; triple‐negative breast cancer; paclitaxel; triple-negative breast cancer; ARID1A; chemotherapy; p38MAPK

Paclitaxel‐based chemotherapy is a common strategy to treat patients with triple‐negative breast cancer (TNBC). As paclitaxel resistance is still a clinical issue in treating TNBCs, identifying molecular markers for predicting pathologic responses to paclitaxel treatment is thus urgently needed. Her...